logo--white

Latest Updates

Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) develops, manufactures, and commercializes regenerative biologics and spinal implant systems for surgical procedures and chronic wound care. Based in Belgrade, Montana, the company operates tissue processing facilities that transform human donor tissue and synthetic materials into medical products used primarily in spine surgery and wound care applications.

Xtant recently announced the sale of two non-core businesses, Coflex and the OUS Paradigm Spine operations. The proceeds from the sale will be used to pay down long-term debt, and improve Xtant’s cash position.

 

Stock Information

 

 

Investor Presentation - Download

feature-company-Xtant-Medical-download

Stock Details

 

Recent News

 

SEC Filings

 
 

 

Xtant Medical Holdings, Inc. At A Glance

Xtant Medical is a global medical technology company that is executing a strategic transformation to concentrate on its core orthobiologics business. The company develops and commercializes a comprehensive portfolio of regenerative products designed to promote bone and tissue healing in spinal and orthopedic procedures. With a record of strong revenue growth, an established U.S. distribution network, and a pending divestiture intended to streamline operations and improve margins, Xtant is positioning itself as a specialized provider in the multi-billion-dollar spine and biologics markets.

 

A Strategic Focus on Higher-Margin Orthobiologics

In July 2025, Xtant announced definitive agreements to sell its spinal implant hardware and international businesses. This pending transaction, expected to close in the third quarter of 2025, represents a significant step in the company’s strategy to focus on its core business: the development and commercialization of higher-margin, best-in-class orthobiologics.

Substantial Market Opportunities

Xtant operates within the Regenerative Biologics market which is inclusive of the $2.5B orthobiologics market, and the $12+B advanced woundcare market.  The company’s products address the entirety of the $2.5 billion U.S. orthobiologics market, which includes segments such as demineralized bone graft, cellular allograft, and growth factor products.

A Demonstrated Record of Strong Revenue Growth

The company has achieved significant revenue growth, reporting $117.3 million for fiscal year 2024, a 28% increase over the prior year. For fiscal year 2025, Xtant expects revenue of $127 million to $131 million. The company noted its estimated revenue growth for 2025 is expected to be 100% organic.

A Differentiated Biologics Product Portfolio

Xtant's portfolio addresses all five major categories of the U.S. orthobiologics market: Demineralized Bone Graft, Cellular Allograft, Allograft, Synthetic Bone Graft, and Marrow-Derived Growth Factor. With the launch of OsteoFactor Pro™ in May 2025, completing their growth factor offering, Xtant became the first vertically integrated company to provide solutions across all these categories.

An Extensive Distribution Network

Xtant maintains exceptional market access in the United States through its established distribution channels. As of December 31, 2024, the company’s network included over 670 independent sales agents and distributors. Additionally, Xtant holds contracts with 450 Integrated Delivery Networks (IDNs) and major Group Purchasing Organizations (GPOs), including Vizient, Premier, and HealthTrust Purchasing Group.

Vertical Integration Strategy

An increasingly important component of Xtant’s strategy is its transition from lower-margin manufacturing to producing higher-margin biologics in-house. The company has expanded its capabilities to internally produce products that were previously outsourced, such as viable bone matrix and growth factors. This vertical integration is intended to increase product margin, improve profitability, and provide greater control over its supply chain.

 
 
 
 
 

Important Resources

Including an At-A-Glance PDF, a document tailored to those who just want quick and summarized information.

Xtant Medical Holdings, Inc. management has decades of industry experience.

Xtant Medical Holdings, Inc. management has decades of industry experience. The team specializes in the medical device sector, leveraging extensive knowledge in operations, manufacturing, quality systems, and public company finance to execute the company's growth strategy in the orthobiologics market.

The Xtant Medical Holdings, Inc. executive leadership regularly updates investors with company news.
Please fill out this form to receive the latest information.

Note: The company can only disclose information that is shared in the public domain through press releases, SEC filings, and other public forums. As securities law and industry regulations require, such information will always be shared with all investors simultaneously.